New DNA testing for liver cancer could improve survival

Google+ Pinterest LinkedIn Tumblr +

liverDetection of small fragments of tumour DNA, known as circulating tumour DNA, in a patient’s pre-surgery serum samples predicts early recurrence of hepatocellular carcinoma and may guide treatment, according to a study published in Cellular and Molecular Gastroenterology and Hepatology.

Hepatocellular carcinoma—the most common type of liver cancer—is the third leading cause of cancer deaths worldwide.

“We uncovered that circulating tumour DNA levels accurately reflect cancer progression and therapy effects on hepatocellularcarcinoma,” said lead study author Atsushi Ono, from Hiroshima University. “With further research, the identification of genome profiles through circulating tumour DNA analysis may guide individualized management of hepatocellular carcinoma.”

The researchers performed whole-genome sequencing on 46 patients undergoing hepatocellular carcinoma resection—removal of the liver or liver transplantation—and for whom pre-surgery and post-surgery serial serum samples were available. By comparing DNA isolated from the tumour to normal DNA from the same patient, they detected mutations in all 46 samples.

While mutations were present in all tumours, only seven patients had detectable circulating tumour DNA in their serum. The presence of circulating tumour DNA was associated with larger tumour size and increased risk of tumour recurrence within two years after liver removal. Circulating tumour DNA levels in serum also increased with disease progression and reflected response to treatments.

Hepatocellular carcinoma is often diagnosed at a late stage, which has resulted in a five-year survival rate of only 11 percent. Identifying a new method to monitor disease progression and identify patients who could benefit from treatment is critical to improve the morbid survival rate associated with this deadly form of liver cancer.

“Circulating tumour DNA analysis represents a potential paradigm shift in personalized medicine for liver cancer,” said Jerrold R. Turner, MD, PhD, AGAF, editor-in-chief, Cellular and Molecular Gastroenterology and Hepatology. “We look forward to seeing future research build on this encouraging data to ultimately improve the effectiveness of therapy against advanced hepatocellular carcinoma.”
[hr] Reference: Ono, Atsushi, et al. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy, Cellular and Molecular Gastroenterology and Hepatology 2015: 1(5): 516-534 www.cmghjournal.org/article/S2352-345X(15)00111-3/fulltext
Source: American Gastroenterological Association

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.